Trevi Therapeutics Inc. (TRVI)
Trevi Therapeutics Statistics
Share Statistics
Trevi Therapeutics has 96.68M shares outstanding. The number of shares has increased by 37.26% in one year.
| Shares Outstanding | 96.68M |
| Shares Change (YoY) | 37.26% |
| Shares Change (QoQ) | 8.19% |
| Owned by Institutions (%) | 78.64% |
| Shares Floating | 57.14M |
| Failed to Deliver (FTD) Shares | 291 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.13M, so 4.63% of the outstanding shares have been sold short.
| Short Interest | 4.13M |
| Short % of Shares Out | 4.63% |
| Short % of Float | 7.12% |
| Short Ratio (days to cover) | 4.53 |
Valuation Ratios
The PE ratio is -8.69 and the forward PE ratio is -8.25. Trevi Therapeutics's PEG ratio is -0.14.
| PE Ratio | -8.69 |
| Forward PE | -8.25 |
| PS Ratio | 0 |
| Forward PS | 2.7 |
| PB Ratio | 4.18 |
| P/FCF Ratio | -10.87 |
| PEG Ratio | -0.14 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Trevi Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.41, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.41 |
| Quick Ratio | 10.41 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 12881 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.84M |
| Employee Count | 26 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -30K |
| Effective Tax Rate | 0.06% |
Stock Price Statistics
The stock price has increased by 100% in the last 52 weeks. The beta is 0.41, so Trevi Therapeutics's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | 100% |
| 50-Day Moving Average | 5.06 |
| 200-Day Moving Average | 3.62 |
| Relative Strength Index (RSI) | 57.3 |
| Average Volume (20 Days) | 2M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -51.52M |
| Net Income | -47.91M |
| EBITDA | -51.52M |
| EBIT | -47.95M |
| Earnings Per Share (EPS) | -0.47 |
Balance Sheet
The company has 34.1M in cash and 1.03M in debt, giving a net cash position of 33.06M.
| Cash & Cash Equivalents | 34.1M |
| Total Debt | 1.03M |
| Net Cash | 33.06M |
| Retained Earnings | -287.05M |
| Total Assets | 110.9M |
| Working Capital | 98.92M |
Cash Flow
In the last 12 months, operating cash flow was -38.26M and capital expenditures -35K, giving a free cash flow of -38.29M.
| Operating Cash Flow | -38.26M |
| Capital Expenditures | -35K |
| Free Cash Flow | -38.29M |
| FCF Per Share | -0.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRVI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TRVI is $20, which is 221.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 221.5% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 28.44 |
| Piotroski F-Score | 1 |